UNSPSC 51263118: Nicainoprol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C21H27N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1UA960P80H, chemically known as 1,2,3,4-tetrahydro-8-(2-hydroxy-3-(isopropylamino)propoxy)-1-(3-pyridylcarbonyl)quinoline but generally known as nicainoprol, which bears US NIH Compound Identifier 71147. European Medicines Agency schedules Nicainoprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09221MIG.

UNSPSC 51263118 Nicainoprol is a Commodity code that appears in state and local procurement records with minimal recent activity. The single recent opportunity on file—Seminole County, Florida's IFB60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023—requests naloxone and drug deactivation systems rather than nicainoprol specifically, suggesting a significant mismatch between the code's nominal scope and what is actually being solicited under it. The opportunity targets 1,900 units of naloxone and 800 safe drug deactivation systems annually, delivered quarterly to the Seminole County Community Health Building in Sanford, Florida, with all shipping and delivery costs included in vendor proposals. Bidders must meet standard compliance requirements including E-Verify authorization, drug-free workplace certification, and specified insurance coverages (workers' compensation, commercial general liability, and professional liability). The initial contract term is two years with an option for a one-year renewal, and the procurement is potentially funded through FEMA, introducing additional federal compliance obligations under the Clean Air Act and Federal Water Pollution Control Act.

The geographic and issuing-body data available from this code are extremely limited. Only Seminole County, a Florida county health agency, appears in recent records. The mismatch between the code name (nicainoprol) and the actual procurement (naloxone and drug deactivation systems) raises questions about whether this code is being applied correctly in state and local procurement systems or whether it genuinely captures pharmaceutical procurement at the commodity level. Firms interested in this code should verify whether the code is actively used for its stated purpose or whether opportunities under it are routinely miscoded, as the single available record does not reflect the code's nominal scope.